Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (GB:0HTB)
LSE:0HTB
Capricor Therapeutics (0HTB) Share Price & Analysis
0 Followers
0HTB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Capricor Therapeutics News
Pre-EarningsCAPR Upcoming Earnings Report: What to Expect?
0HTB FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is in 42 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 07, 2023. The company reported -€0.274 earnings per share for the quarter, beating the consensus estimate of -€0.331 by €0.057.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -€0.32.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 25,776,867 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.274 in its last earnings report, beating expectations of -€0.331. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Oracle Investment Management Inc. It holds Capricor Therapeutics’s shares valued at N/A.
---
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.89%
12-Months-Change
Fundamentals
Return on Equity
-272.38%
Trailing 12-Months
Asset Growth
-20.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
Capricor Therapeutics
―
Fate Therapeutics
―
Rocket Pharmaceuticals
―
Bluebird Bio
―
---